This paper is also fascinating, since it clarifies the mystery, recently discussed directly in the ezetimibe thread, how
ezitimibe works to block Hbv entry, as shown by ulrike prozer in the hepaRG system. It is simply a NTCP blocker, moderatly potent. Of note, blockage of this receptor, NTCP, is also the mechanism by which Myrcludex works as an entry inhibitor. It is the membrane protein that normally transports bile acids from the portal blood into the hepatocytes for recycling.